enGene Holdings
ENGN
Market cap $364M

7.14 USD

+0.13

1.85%

At close Jan 17, 4:00 PM EST

After hours

7.12

-0.02

0.28%

1 day

1.85%

5 days

-3.64%

1 month

13.51%

3 months

-23.23%

6 months

-21.28%

Year to date

1.13%

1 year

-4.80%

5 years

-64.30%

10 years

-64.30%

About: enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Employees: 57

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,823 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

150% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 4

1.01% more ownership

Funds ownership: 76.54% [Q2] → 77.55% (+1.01%) [Q3]

0% more funds holding

Funds holding: 30 [Q2] → 30 (+0) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

28% less capital invested

Capital invested by funds: $318M [Q2] → $228M (-$90.7M) [Q3]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$18

152%

upside

Avg. target

$22

208%

upside

High target

$25

250%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Silvan Tuerkcan 30% 1-year accuracy 17 / 56 met price target	152%upside $18	Market Outperform Reiterated	23 Dec 2024
HC Wainwright & Co. Andres Maldonado 28% 1-year accuracy 13 / 46 met price target	250%upside $25	Buy Initiated	23 Dec 2024
Raymond James Sean McCutcheon 0% 1-year accuracy 0 / 4 met price target	222%upside $23	Outperform Initiated	27 Nov 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

How Much Upside is Left in enGene Holdings Inc. (ENGN)? Wall Street Analysts Think 238.77%

The average of price targets set by Wall Street analysts indicates a potential upside of 238.8% in enGene Holdings Inc. (ENGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in enGene Holdings Inc. (ENGN)? Wall Street Analysts Think 238.77%

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today reported the grant of inducement equity awards to.

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Zacks Investment Research

enGene Holdings Inc. (ENGN) Upgraded to Strong Buy: Here's Why

enGene Holdings Inc. (ENGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

enGene Holdings Inc. (ENGN) Upgraded to Strong Buy: Here's Why

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), announced its financial results for the full year end.

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook

enGene is working toward an approval similar to what IBRX got with Anktiva, although without needing BCG co-administration. NMIBC remains an area of unmet need, although it may not be SO unmet that the FDA gives ENGN a generous approval on single-arm data. Considering the current price, and their favorable financial position, my outlook from here for the company is very positive.

enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook

Zacks Investment Research

Here's Why enGene Holdings Inc. (ENGN) is Poised for a Turnaround After Losing -16.9% in 4 Weeks

enGene Holdings Inc. (ENGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why enGene Holdings Inc. (ENGN) is Poised for a Turnaround After Losing -16.9% in 4 Weeks

enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that Alex Nichols, Ph.D., Chief Strategy.

enGene to Participate in Upcoming Investor Conferences

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that Ron Cooper, Chief Executive Officer.

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

enGene Announces $60 Million Private Placement Financing

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that it has agreed to sell 6,758,311 of.

enGene Announces $60 Million Private Placement Financing

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today reported the grant of an inducement equity award t.

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

See News Rankings

Charts implemented using Lightweight Charts™